QUESTCOR PHARMACEUTICALS INC 4
4 · QUESTCOR PHARMACEUTICALS INC · Filed Aug 18, 2014
Insider Transaction Report
Form 4
Martin G. Kelly
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2014-08-14−1,160→ 0 totalExercise: $61.60Exp: 2023-06-07→ Common Stock (1,160 underlying) - Disposition to Issuer
Common Stock
2014-08-14−2,812→ 0 total
Footnotes (4)
- [F1]Pursuant to Agreement and Plan of Merger, dated April 5, 2014 (the "Merger Agreement"), by and among Mallinckrodt plc ("Mallinckrodt"), Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. ("Questcor"), Mallinckrodt acquired Questcor in a merger transaction (the "Merger") which closed at 4:30 p.m. EST, on August 14, 2014 (the "Effective Time"). At the Effective Time, each share of Questcor common stock (except for certain shares defined in the Merger Agreement) converted into the right to receive, without interest, (a) $30.00 in cash and (b) 0.897 of an ordinary share of Mallinckrodt, in exchange for such share of Questcor common stock ("Merger Consideration").
- [F2](Continued from footnote 1) Pursuant to terms of the Merger, each outstanding Questcor restricted stock award held by Questcor non-employee directors will be cancelled and converted into the right to receive Merger Consideration in respect of each share of Questcor common stock underlying the Questcor restricted stock award.
- [F3]Pursuant to terms of the Merger, at the Effective Time, each Questcor stock option, whether vested or unvested, held by Questcor non-employee directors converted into the right to receive the Merger Consideration with respect to each share of Company common stock subject to such option immediately prior to the effective time of the Merger, net of the applicable exercise price.
- [F4]Fully exercisable.